<?xml version='1.0' encoding='utf-8'?>
<document id="24424534"><sentence text="Periplocymarin is a potential natural compound for drug development: highly permeable with absence of P-glycoprotein efflux and cytochrome P450 inhibitions."><entity charOffset="0-14" id="DDI-PubMed.24424534.s1.e0" text="Periplocymarin" /></sentence><sentence text="Periplocymarin, a cardiac glycoside isolated from Periploca sepium (P"><entity charOffset="0-14" id="DDI-PubMed.24424534.s2.e0" text="Periplocymarin" /><entity charOffset="26-35" id="DDI-PubMed.24424534.s2.e1" text="glycoside" /><pair ddi="false" e1="DDI-PubMed.24424534.s2.e0" e2="DDI-PubMed.24424534.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24424534.s2.e0" e2="DDI-PubMed.24424534.s2.e1" /></sentence><sentence text=" sepium) and Periploca graeca (P" /><sentence text=" graeca), is a potential anti-cancer compound" /><sentence text=" The aim of the study was to investigate the potential for periplocymarin to interact with P-glycoprotein (P-gp) and to inhibit cytochrome P450s known to be expressed in the human small intestine"><entity charOffset="59-73" id="DDI-PubMed.24424534.s5.e0" text="periplocymarin" /></sentence><sentence text=" The in vitro and in situ permeability of periplocymarin were studied using Madin-Darby canine kidney (MDCK-II-WT) cells transfected with or without the human multidrug resistance (MDR1) gene and the single-pass perfused rat intestinal model" /><sentence text=" The cell system exhibited high functional activity and a net efflux ratio (NER) of 4" /><sentence text="32 after transport of Rhodamine 123 (R123) (the P-gp substrate)" /><sentence text=" Periplocymarin is highly permeable (Papp  &gt; 10 × 10(-6) cm/s; Peff(rat)  &gt; 5"><entity charOffset="1-15" id="DDI-PubMed.24424534.s9.e0" text="Periplocymarin" /></sentence><sentence text="09 × 10(-5) cm/s) and independent of P-gp influences" /><sentence text=" The NER at 100 μm periplocymarin (0"><entity charOffset="19-33" id="DDI-PubMed.24424534.s11.e0" text="periplocymarin" /></sentence><sentence text="8) was unchanged in the presence of cyclosporine A (a non-specific P-gp inhibitor) (0"><entity charOffset="36-50" id="DDI-PubMed.24424534.s12.e0" text="cyclosporine A" /></sentence><sentence text="82)" /><sentence text=" In the single-pass intestinal model, the Peff (rat) of 5 µg/ml periplocymarin (5"><entity charOffset="64-78" id="DDI-PubMed.24424534.s14.e0" text="periplocymarin" /></sentence><sentence text="490 × 10(-5) cm/s) did not change in the presence of cyclosporine A (5"><entity charOffset="53-67" id="DDI-PubMed.24424534.s15.e0" text="cyclosporine A" /></sentence><sentence text="394 × 10(-5) cm/s)" /><sentence text=" In the R123-inhibition assay, periplocymarin did not competitively inhibit P-gp"><entity charOffset="31-45" id="DDI-PubMed.24424534.s17.e0" text="periplocymarin" /></sentence><sentence text=" The inhibitory potential of periplocymarin on cytochrome P450 (CYP450s) was also studied"><entity charOffset="29-43" id="DDI-PubMed.24424534.s18.e0" text="periplocymarin" /></sentence><sentence text=" Periplocymarin (5, 50 μm) did not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6 or CYP3A4"><entity charOffset="1-15" id="DDI-PubMed.24424534.s19.e0" text="Periplocymarin" /></sentence><sentence text=" Thus, periplocymarin is unlikely to encounter drug-drug interactions with P-gp and CYP450s"><entity charOffset="7-21" id="DDI-PubMed.24424534.s20.e0" text="periplocymarin" /></sentence><sentence text=" Periplocymarin could be taken forward for further studies in drug development to test bioavailability, Phase II enzyme interactions and additional transporter interactions"><entity charOffset="1-15" id="DDI-PubMed.24424534.s21.e0" text="Periplocymarin" /></sentence><sentence text="" /></document>